Contents
Download PDF
pdf Download XML
222 Views
1 Downloads
Share this article
Research Article | Volume 4 Issue 1 (, 1998) | Pages 1 - 8
Impact of prosthesis-patient mismatch on hemodynamic and symptomatic status, morbidity and mortality after aortic valve replacement with a bioprosthetic heart valve
1
Department of Cardiology, Quebec Heart Institute, Ste Foy, Canada
Under a Creative Commons license
Open Access
Received
Sept. 19, 1998
Revised
Oct. 19, 1998
Accepted
Nov. 23, 1998
Published
Dec. 23, 1998
Abstract

Background and aims of the study: Previous studies have shown that the effective orifice area of an aortic prosthetic valve may be too small in relation to the patient's body surface area, resulting in abnormally high gradients. The consequences of this condition, termed prosthesis-patient mismatch, have not been fully studied. The study objective was to determine if the condition has a detrimental effect on symptomatic and hemodynamic status, morbidity and mortality of patients undergoing aortic valve replacement.

Methods: A cohort of 392 patients was prospectively followed for up to seven years after implantation of a Medtronic Intact bioprosthesis. Doppler echocardiography was performed annually in 72 patients. Based on previous studies, presence of mismatch was defined as an indexed valve area < or = 0.85 cm2/m2.

Results: Mismatch was associated with less postoperative improvement of NYHA functional class (p < 0.009) independently of other predictors, such as age and preoperative functional class, but had no significant impact on patient survival (mismatch: 75 +/- 4%, no mismatch: 79 +/- 3%; p = 0.59) and valve-related morbidity up to seven years. Cardiac index was similar in patients with and without mismatch up to three years after operation but decreased significantly thereafter only in patients with mismatch (-0.54 +/- 0.32 versus -0.17 +/- 0.49 l/min/m2; p = 0.04). Likewise, the mean transprosthetic gradient, which was higher at one year after operation in patients with mismatch (22 +/- 8 versus 15 +/- 7 mmHg), increased significantly (+6 +/- 6 versus +1 +/- 1 mmHg; p = 0.008) only in this group during follow up.

Conclusions: Patients with mismatch have less symptomatic improvement and worse hemodynamics that continue to deteriorate with time. However, medium-term prognosis (up to seven years) is relatively good. Further studies are necessary to determine the longer-term effects of mismatch on morbidity and mortality.

Keywords
Recommended Articles
Research Article
Role of Metformin in Modulating Serum Ghrelin Levels in Obesity
Published: 30/12/2023
Download PDF
Read Article
Research Article
Morphometric Analysis of the Human Mitral Valve: A Cadaveric Study
...
Published: 19/08/2025
Download PDF
Read Article
Research Article
Impact of Metformin Therapy on Serum Adiponectin Levels in Obese Individuals
Published: 14/08/2025
Download PDF
Read Article
Research Article
Prospective Study on Functional Outcome of CTEV By Ponseti Method of Cast Application
...
Published: 31/07/2025
Download PDF
Read Article
© Copyright Journal of Heart Valve Disease